Ignite Creation Date:
2024-05-06 @ 8:09 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06272565
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-01
First Post:
2024-02-01
Brief Title:
Exploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage
Sponsor:
Zhongshan Ophthalmic Center Sun Yat-sen University
Organization:
Zhongshan Ophthalmic Center Sun Yat-sen University
Study Overview
Official Title:
An Approach of Exploring the Mechanism of the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage Based on Metabolomics Methods
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DR
Brief Summary:
Diabetic retinopathy DR is one of the most serious microvascular complications of diabetes Early diagnosis and treatment of diabetes is the key to prevent visual impairment in DR patients This study aims to use a non-targeted metabolomics detection technique combined with ultra-high performance liquid chromatography time-of-flight mass spectrometry to analyze the metabolomics profile in aqueous humor sample of DR patents and further explore the mechanism of the relationship between differential metabolites and their metabolic pathways with NLRP3 activation in DR inflammatory damage DR patients with macular edema will receive anti-vascular endothelial growth factor anti-VEGF treatment these patients will be divided into two groups responders group and non-responders group
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None